About US
Contact us
-
The Fourth PhExFEST & International Pharmaceutical Preparations and Pharmaceutical Excipients Development Forum has been successfully concludedThe 4th PhExFEST & 2014 International Pharmaceutical Preparations and Pharmaceutical Excipients Development Forum held in Jinan Wanda Hyatt Hotel successfully On June 19-22, 2014! The PhExFEST att2014/6/26
-
Abbott to acquire Russian pharmaceutical companyUS-based healthcare company Abbott has entered into a definitive agreement to acquire Veropharm, a Russia-based pharmaceutical firm. Under the agreement, Abbott will acquire Garden Hills, which curre2014/6/26
-
Bayer’s Nexavar receives Japanese approvalBayer HealthCare has obtained approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its Nexavar (sorafenib) for treatment of patients with unresectable differentiated thyroid ca2014/6/26
-
Celsion completes acquisition of EGENCelsion has completed the acquisition of EGEN, including its Phase Ib product candidate EGEN-001 and therapeutic platform technologies, TheraPlas, TheraSilence, and RAST. Under the terms of the agree2014/6/25
-
FDA accepts Cubist’s new drug application for ceftolozane/tazobactam with priority reviewCubist Pharmaceuticals' new drug application for its ceftolozane/tazobactam for treatment of complicated urinary tract infections and complicated intra-abdominal infections has been accepted by the US2014/6/25
-
CDC says 75 Atlanta-based staff possibly exposed to anthraxThe Centers for Disease Control and Prevention (CDC) has reported that 75 Atlanta-based staff may have been unintentionally exposed to live Bacillus anthracis, the cause of the anthrax disease, and ar2014/6/24
-
Takeda decides to terminate prostate cancer drug developmentJapan-based Takeda Pharmaceutical has announced the termination of orteronel (TAK-700) development for prostate cancer in Japan, the US and Europe. The company has voluntarily decided to end the deve2014/6/24
-
Janssen enters into licence agreement with Vertex for influenza A drugJanssen Pharmaceuticals and Vertex Pharmaceuticals have entered into an exclusive licence agreement to develop, manufacture and commercialise VX-787, an investigational medicine for treatment of influ2014/6/23
-
Pfizer in cancer immunotherapy collaboration with CellectisPfizer has announced a global strategic collaboration with France-based Cellectis for development of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at selec2014/6/23
-
Pfizer submits biologics license application to FDA for meningitis B vaccinePfizer has submitted a biologics licence application to the US Food and Drug Administration (FDA) for approval of its vaccine candidate bivalent recombinant LP2086 (rLP2086) to help protect against in2014/6/20